PureTech Health plc (FRA:0VQ)

Germany flag Germany · Delayed Price · Currency is EUR
1.400
+0.010 (0.72%)
Last updated: Dec 4, 2025, 7:27 PM CET
-29.29%
Market Cap 337.69M
Revenue (ttm) 5.44M
Net Income (ttm) 43.15M
Shares Out n/a
EPS (ttm) 0.17
PE Ratio 7.83
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 600
Open 1.380
Previous Close 1.390
Day's Range 1.380 - 1.400
52-Week Range 1.160 - 2.180
Beta n/a
RSI 38.63
Earnings Date Nov 28, 2025

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 56
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0VQ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.